Clinical Trial Update: Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating discontinuation versus dose reduction of tocilizumab in well-controlled giant cell arteritis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Giant Cell Arteritis (GCA) | Phase 2 | Status: RECRUITING